Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹1,419 Cr
down ₹85.9 Cr vs Jan 2016
- Stocks held
- 16
- 1 vs Jan 2016
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In February 2016 it disclosed 16 stocks worth ₹1,419 Cr, down ₹85.9 Cr from Jan 2016. Its largest positions were Abbott India Limited (12.2%), Sun Pharmaceutical Industries Limited (11.7%), Sanofi India Limited (11.2%); the ten largest together made up 88.0% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 97.5% of its equity. Cash and debt stood at 2.4%. Compared with Jan 2016 the fund entered 0 new stocks and exited 1.
Against 227 other Sectoral / Thematic funds
Concentration
100%
Top-10 weight is higher than 100% of peers
Breadth
2%
Holds more stocks than 2% of peers
Cash
33%
Holds more cash than 33% of peers
Holdings in February 2016
Download CSVEvery line the fund disclosed, with the change against Jan 2016. Click a column to sort; click a company to see every fund that owns it.
| Abbott India Limited | 12.23% | up 0.03 pts | ₹174 Cr | down ₹10.1 Cr | Trimmed |
| Sun Pharmaceutical Industries Limited | 11.72% | up 0.40 pts | ₹166 Cr | down ₹4 Cr | Trimmed |
| Sanofi India Limited | 11.20% | up 0.81 pts | ₹159 Cr | up ₹2.5 Cr | Added |
| Divi's Laboratories Limited | 9.72% | up 0.01 pts | ₹138 Cr | down ₹8.2 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 9.01% | up 1.25 pts | ₹128 Cr | up ₹11.1 Cr | Added |
| Cipla Limited | 8.88% | down 0.65 pts | ₹126 Cr | down ₹17.4 Cr | Trimmed |
| Zydus Lifesciences Limited | 7.76% | up 2.30 pts | ₹110 Cr | up ₹28 Cr | Added |
| Aurobindo Pharma Limited | 6.47% | up 0.93 pts | ₹91.8 Cr | up ₹8.4 Cr | Added |
| Lupin Limited | 6.19% | down 0.93 pts | ₹87.8 Cr | down ₹19.3 Cr | Trimmed |
| IPCA Laboratories Limited | 4.79% | down 1.32 pts | ₹68 Cr | down ₹24 Cr | Trimmed |
| FDC Limited | 3.64% | down 0.03 pts | ₹51.7 Cr | down ₹3.6 Cr | Trimmed |
| Cash, TREPS & receivables | 2.41% | up 0.43 pts | ₹34.2 Cr | up ₹4.5 Cr | Added |
| Biocon Limited | 2.15% | up 0.04 pts | ₹30.5 Cr | down ₹1.3 Cr | Trimmed |
| Indoco Remedies Limited | 1.68% | down 0.22 pts | ₹23.9 Cr | down ₹4.7 Cr | Trimmed |
| Alkem Laboratories Limited | 0.90% | down 0.34 pts | ₹12.7 Cr | down ₹5.8 Cr | Trimmed |
| Narayana Hrudayalaya Limited | 0.73% | down 0.09 pts | ₹10.4 Cr | down ₹2 Cr | Trimmed |
| Procter & Gamble Health Limited | 0.52% | down 0.02 pts | ₹7.3 Cr | down ₹78 L | Trimmed |
What changed, Jan 2016 to Feb 2016
New New positions (0)
None.
Exited Exited (1)
- Dr. Lal Path Labs Limitedwas 0.9% · ₹14.1 Cr
Added Biggest additions
- Zydus Lifesciences Limitedup ₹28 Cr (+2.30% pts)
- Dr. Reddy's Laboratories Limitedup ₹11.1 Cr (+1.25% pts)
- Aurobindo Pharma Limitedup ₹8.4 Cr (+0.93% pts)
- Sanofi India Limitedup ₹2.5 Cr (+0.81% pts)
Biggest reductions
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jan 2016, the weight rose most in Pharmaceuticals & Biotechnology (+1.3 pts), and fell most in Healthcare Services (−1.1 pts) and Pharmaceuticals (−0.2 pts).
- Pharmaceuticals & Biotechnology96.2% → 97.5%+1.3 pts
- Healthcare Services1.8% → 0.7%−1.1 pts
- Pharmaceuticals2.0% → 1.7%−0.2 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Feb 2013 | Feb 2015 | Aug 2015 | Nov 2015 | Jan 2016 | Feb 2016 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 79.5% | 92.8% | 95.6% | 95.6% | 96.2% | 97.5% |
| Pharmaceuticals | 14.9% | 6.6% | 2.5% | 2.5% | 2.0% | 1.7% |
| Healthcare Services | 0.1% | — | 1.9% | 1.8% | 1.8% | 0.7% |
Allocation in Feb 2016change vs Jan 2016
- Pharmaceuticals & Biotechnology (14)97.5%▲ 1.3 pts
- Pharmaceuticals (1)1.7%▼ 0.2 pts
- Healthcare Services (1)0.7%▼ 1.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Feb 2016
2.4%
▼ 1.2 pts vs Jan 2016
- Cash alone
- 2.4%
- cash and net receivables
- A year earlier
- 1.2%
- Feb 2015 · now ▲ 1.2 pts
- Last 12 months
- 0.9% – 9.6%
- lowest to highest · record 9.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.